Moderna to submit Covid-19 vaccine to FDA; full results show 94% efficacy
December 17, 2020 coronavirus news | CNN
A Single Immunization with Nucleoside-Modified mRNA Vaccines Elicits Strong Cellular and Humoral Immune Responses against SARS-CoV-2 in Mice. - Abstract - Europe PMC
mRNA-lipid nanoparticle COVID-19 vaccines: Structure and stability - ScienceDirect
RNA vaccine - Wikipedia
An mRNA Vaccine against SARS-CoV-2 — Preliminary Report | NEJM
Healthcare Provider Q&A
A Single Immunization with Nucleoside-Modified mRNA Vaccines Elicits Strong Cellular and Humoral Immune Responses against SARS-CoV-2 in Mice. - Abstract - Europe PMC
mRNA-lipid nanoparticle COVID-19 vaccines: Structure and stability - ScienceDirect
SARS-CoV-2 mRNA Vaccine Development Enabled by Prototype Pathogen Preparedness | bioRxiv
A Single Immunization with Nucleoside-Modified mRNA Vaccines Elicits Strong Cellular and Humoral Immune Responses against SARS-CoV-2 in Mice. - Abstract - Europe PMC
A Single Immunization with Nucleoside-Modified mRNA Vaccines Elicits Strong Cellular and Humoral Immune Responses against SARS-CoV-2 in Mice. - Abstract - Europe PMC
Vaccines for COVID‐19 - Tregoning - 2020 - Clinical & Experimental Immunology - Wiley Online Library
Vaccines | Free Full-Text | Current Status of Zika Virus Vaccines: Successes and Challenges | HTML
Preclinical and Clinical Demonstration of Immunogenicity by mRNA Vaccines against H10N8 and H7N9 Influenza Viruses
Frontiers | Current Efforts in the Development of Vaccines for the Prevention of Zika and Chikungunya Virus Infections | Immunology
Immune-mediated approaches against COVID-19 | Nature Nanotechnology
Vaccines | Free Full-Text | An Update on Self-Amplifying mRNA Vaccine Development | HTML
FDA approves potential COVID-19 vaccine by Moderna for second-stage study - UPI.com
A Single Immunization with Nucleoside-Modified mRNA Vaccines Elicits Strong Cellular and Humoral Immune Responses against SARS-C
